VYNDAMAX Drug Patent Profile
✉ Email this page to a colleague
When do Vyndamax patents expire, and when can generic versions of Vyndamax launch?
Vyndamax is a drug marketed by Foldrx Pharms and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.
This drug has sixty-six patent family members in twenty-seven countries.
The generic ingredient in VYNDAMAX is tafamidis. One supplier is listed for this compound. Additional details are available on the tafamidis profile page.
DrugPatentWatch® Generic Entry Outlook for Vyndamax
Vyndamax was eligible for patent challenges on May 3, 2023.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be August 31, 2035. This may change due to patent challenges or generic licensing.
There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for VYNDAMAX
| International Patents: | 66 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 70 |
| Patent Applications: | 36 |
| Drug Prices: | Drug price information for VYNDAMAX |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VYNDAMAX |
| DailyMed Link: | VYNDAMAX at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VYNDAMAX
Generic Entry Date for VYNDAMAX*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for VYNDAMAX
US Patents and Regulatory Information for VYNDAMAX
VYNDAMAX is protected by three US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VYNDAMAX is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting VYNDAMAX
Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)
Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)
FDA Regulatory Exclusivity protecting VYNDAMAX
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) IN ADULTS TO REDUCE CARDIOVASCULAR MORTALITY AND CARDIOVASCULAR-RELATED HOSPITALIZATION
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Foldrx Pharms | VYNDAMAX | tafamidis | CAPSULE;ORAL | 212161-001 | May 3, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Foldrx Pharms | VYNDAMAX | tafamidis | CAPSULE;ORAL | 212161-001 | May 3, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Foldrx Pharms | VYNDAMAX | tafamidis | CAPSULE;ORAL | 212161-001 | May 3, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Foldrx Pharms | VYNDAMAX | tafamidis | CAPSULE;ORAL | 212161-001 | May 3, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for VYNDAMAX
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Pfizer Europe MA EEIG | Vyndaqel | tafamidis | EMEA/H/C/002294 Vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment. |
Authorised | no | no | yes | 2011-11-16 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for VYNDAMAX
When does loss-of-exclusivity occur for VYNDAMAX?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 1778
Estimated Expiration: ⤷ Try a Trial
Australia
Patent: 15313875
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 2017003421
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 03194
Estimated Expiration: ⤷ Try a Trial
China
Patent: 6715405
Patent: 6‑羧基‑2‑(3,5‑二氯苯基)苯并噁唑的结晶固体形式 (Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole)
Estimated Expiration: ⤷ Try a Trial
Patent: 5368313
Patent: 6-羧基-2-(3,5-二氯苯基)苯并噁唑的结晶固体形式 (Crystalline solid forms of 6-carboxy-2-(3, 5-dichlorophenyl) benzoxazole)
Estimated Expiration: ⤷ Try a Trial
Croatia
Patent: 0211834
Estimated Expiration: ⤷ Try a Trial
Cyprus
Patent: 24843
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 91461
Estimated Expiration: ⤷ Try a Trial
Patent: 77993
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 56583
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 57525
Estimated Expiration: ⤷ Try a Trial
Patent: 16065042
Estimated Expiration: ⤷ Try a Trial
Patent: 20055832
Estimated Expiration: ⤷ Try a Trial
Patent: 22024014
Estimated Expiration: ⤷ Try a Trial
Patent: 23134645
Estimated Expiration: ⤷ Try a Trial
Lithuania
Patent: 91461
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 17002954
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 91461
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 91461
Estimated Expiration: ⤷ Try a Trial
Russian Federation
Patent: 92252
Estimated Expiration: ⤷ Try a Trial
Patent: 17107235
Estimated Expiration: ⤷ Try a Trial
Serbia
Patent: 634
Estimated Expiration: ⤷ Try a Trial
Singapore
Patent: 201700958Y
Estimated Expiration: ⤷ Try a Trial
Slovenia
Patent: 91461
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 2004059
Estimated Expiration: ⤷ Try a Trial
Patent: 170040314
Patent: 6-카르복시-2--벤족사졸의 결정질 고체 형태 (6--2-35-- CRYSTALLINE SOLID FORMS OF 6-CARBOXY-2-35-DICHLOROPHENYL-BENZOXAZOLE)
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 01785
Estimated Expiration: ⤷ Try a Trial
Taiwan
Patent: 44902
Estimated Expiration: ⤷ Try a Trial
Patent: 1613880
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VYNDAMAX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2003303196 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2004056315 | ⤷ Try a Trial | |
| Croatia | P20211834 | ⤷ Try a Trial | |
| Canada | 2800237 | COMPOSITIONS ET METHODES PERMETTANT DE STABILISER LA TRANSTHYRETINE ET D'INHIBER UN MAUVAIS REPLIEMENT DE LA TRANSTHYRETINE (COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VYNDAMAX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1587821 | C20120001 00050 | Estonia | ⤷ Try a Trial | PRODUCT NAME: VYNDAQEL - TAFAMIDIS;REG NO/DATE: C(2011)8519 FINAL 16.11.2011 |
| 1587821 | 1290005-6 | Sweden | ⤷ Try a Trial | PERIOD OF VALIDITY AFTER CORRECTION (FROM - UNTIL): 20231220 - 20261117 |
| 1587821 | 91935 | Luxembourg | ⤷ Try a Trial | 91935, EXPIRES: 20261116 |
| 1587821 | C01587821/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: TAFAMIDIS; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67083 09.03.2020 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
